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ABSTRACT The global threat to public health posed by emerging multidrug-resistant bacteria in the past few years necessitates
the development of novel approaches to combat bacterial infections. Endolysins encoded by bacterial viruses (or phages) repre-
sent one promising avenue of investigation. These enzyme-based antibacterials efficiently kill Gram-positive bacteria upon con-
tact by specific cell wall hydrolysis. However, a major hurdle in their exploitation as antibacterials against Gram-negative patho-
gens is the impermeable lipopolysaccharide layer surrounding their cell wall. Therefore, we developed and optimized an
approach to engineer these enzymes as outer membrane-penetrating endolysins (Artilysins), rendering them highly bactericidal
against Gram-negative pathogens, including Pseudomonas aeruginosa and Acinetobacter baumannii. Artilysins combining a
polycationic nonapeptide and a modular endolysin are able to kill these (multidrug-resistant) strains in vitrowith a 4 to 5 log
reduction within 30 min.We show that the activity of Artilysins can be further enhanced by the presence of a linker of increasing
length between the peptide and endolysin or by a combination of both polycationic and hydrophobic/amphipathic peptides.
Time-lapse microscopy confirmed the mode of action of polycationic Artilysins, showing that they pass the outer membrane to
degrade the peptidoglycan with subsequent cell lysis. Artilysins are effective in vitro (human keratinocytes) and in vivo (Caeno-
rhabditis elegans).
IMPORTANCE Bacterial resistance to most commonly used antibiotics is a major challenge of the 21st century. Infections that can-
not be treated by first-line antibiotics lead to increasing morbidity andmortality, while millions of dollars are spent each year by
health care systems in trying to control antibiotic-resistant bacteria and to prevent cross-transmission of resistance. Endoly-
sins—enzymes derived from bacterial viruses—represent a completely novel, promising class of antibacterials based on cell wall
hydrolysis. Specifically, they are active against Gram-positive species, which lack a protective outer membrane and which have a
low probability of resistance development. Wemodified endolysins by protein engineering to create Artilysins that are able to
pass the outer membrane and become active against Pseudomonas aeruginosa and Acinetobacter baumannii, two of the most
hazardous drug-resistant Gram-negative pathogens.
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Endolysins are produced by bacteriophages at the end of theirlytic replication cycle to hydrolyze the bacterial cell wall for
progeny release. In the last decade, it has been extensively demon-
strated that the addition of recombinant purified endolysin to
susceptible Gram-positive bacteria, including Staphylococcus,
Streptococcus, and Bacillus species, kills the bacteria through cell
lysis, both in vitro and in various animal infection models of hu-
man disease (1–4). Their rapid action, high specificity, nontoxic-
ity, high efficiency, and low probability of resistance development
make them promising, novel enzyme-based antibacterials (5).
The expansion of endolysins as antibacterials against important
Gram-negative pathogens is hindered by the outer membrane.
Although some endolysins show limited membrane-destabilizing
properties (6, 7), this outer membrane poses a highly effective
permeability barrier for the passage of harmful compounds, in-
cluding endolysins and many other antibacterial compounds (8).
We have previously shown that the use of high hydrostatic pres-
sure (in the range of 150 to 200 MPa) (9) or outer membrane
permeabilizers (10) strongly increases the access of endolysins to
the Gram-negative peptidoglycan layer. In this study, we devel-
oped an efficient methodology of protein engineering of endoly-
sins to generate highly antibacterial, outermembrane-penetrating
endolysins termed Artilysins independently of protein transport
systems (11). We show that Artilysins cause 4 to 5 log killing of
different (clinically relevant) Gram-negative species in vitro and
are also effective in vivo.
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RESULTS
Artilysins: proof of concept. The rationale behind Artilysins is
based on the modification of endolysins with lipopolysaccharide
(LPS)-destabilizing peptides. The LPS layer is stabilized through
ionic interactions between divalent cations and phosphate groups
and hydrophobic stacking of the lipid A moiety (12). Seven pep-
tides were selected for their (putative) LPS-destabilizing activity
based on different physicochemical properties (cationic, hydro-
phobic or amphipathic) that interfere with these stabilizing forces
(see Table S1 in the supplemental material) (13–16). To test this
engineering concept, the two most active endolysins (OBPgp279
and PVP-SE1gp146) from our collection of characterized endoly-
sins (7) were used. OBPgp279 originates from Pseudomonas fluo-
rescens phage OBP (phiKZ-like; Myoviridae) and PVP-SE1gp146
from Salmonella enterica serovar Enteritidis phage PVP-SE1 (rV5-
like; Myoviridae). Both endolysins feature a modular structure
with one (PVP-SE1gp146) or two (OBPgp279) N-terminal
peptidoglycan-binding (PBD-like) domains and aC-terminal cat-
alytic domain (glycoside hydrolase 19-like family, lysozyme-like
superfamily). This domain configuration is rare among endoly-
sins targeting Gram-negative peptidoglycan and is associated with
strongly increased enzymatic activity (7, 17, 18). In addition,
OBPgp279 has a moderate intrinsic antibacterial effect on Pseu-
domonas aeruginosa (1.10 log reduction) (7). Fourteen different
Artilysins (LoGT-001 to LoGT-014) (Fig. 1; see also Tables S2 and
S3 in the supplemental material) were produced and purified, the
effect of the respective fusions on protein yield was determined
(see Table S4), and the antibacterial activity of the different Arti-
lysins against P. aeruginosa, Escherichia coli, and Salmonella en-
terica serovar Typhimurium was evaluated (see Table S5). The
fusion of each LPS-destabilizing peptide to endolysin PVP-
SE1gp146 resulted in an enhanced bactericidal activity against
P. aeruginosa in comparison to wild-type PVP-SE1gp146, but the
effect was most prominent for the polycationic nonapeptide
(PCNP). The latter is the only peptide that also increases the in-
trinsic antibacterial effect of OBPgp279, whereas the other pep-
tides appear to inhibit this intrinsic antibacterial effect (Fig. 2A).
The highest reduction was obtained with LoGT-001, combining
the PCNP tag and OBPgp279, with a 2.61 0.09 log reduction in
only 30min. Thus, the PCNP tag emerged as themost appropriate
peptide to confer antibacterial activity to (otherwise nonantibac-
terial) endolysins.
We also performed the same experiment in the presence of
0.5 mM EDTA, an outer membrane permeabilizer that shows
strong synergy with endolysins (10). For both LoGT-001 and
LoGT-008, combining the PCNP tag with OBPgp279 and PVP-
SE1gp146, respectively, the synergy with EDTA is not compro-
mised by the modification: both the fusion to the PCNP tag and
the addition of a low concentration of EDTA confer antibacterial
activity against P. aeruginosa PAO1 and Br667 (a multidrug-
resistant clinical isolate [19]) to the wild-type endolysins or fur-
ther improve this activity. A maximal reduction of P. aeruginosa
PAO1, at 5.38 0.19 log, was observed with LoGT-001 (Fig. 2B).
This indicates that the PCNP tag has a mode of action different
from that of EDTA. This synergy constitutes a potential benefit for
the topical applicability of Artilysins. Although E. coli and S. Ty-
phimurium were also most strongly affected by PCNP-fused en-
dolysins, the general effect was here significantly smaller, with
maximal reductions of 1.70 0.05 (E. coli) and 0.91 0.04 (S. Ty-
phimurium) (see Table S5).
Mode of action of Artilysins.We used time-lapse microscopy
to observe themode of killing by a PCNP-fused endolysin. LoGT-
008wasmixedwith P. aeruginosa PAO1 in the presence of 0.5mM
EDTA and immediately incubated on an agar pad formicroscopic
observation. Within minutes, the first rods lysed abruptly (see
movie http://www.biw.kuleuven.be/dp/logt/phagesinteraction/
movieS1.avi). Even before observation could start (1 min), lysis
of some cells had likely occurred, as witnessed by the presence of
the remaining debris of lysed cells. Other rods lysed one by one at
up to 1 h after addition of LoGT-008. The involvement of pepti-
doglycan degradation in the lysis process was shown by the tran-
sient formation of round or lemon-shaped spheroplasts before
complete lysis took place. Septal peptidoglycan appeared to be
degraded as well, suggested by the fusion of spheroplasts that orig-
inate from almost completely constricted cells (Fig. 3). These ob-
servations are fully consistent with the Artilysin concept, stating
that the LPS layer is disturbed by the polycationic nonapeptide,
followed by penetration of the endolysinmoiety through the outer
membrane and subsequent lysis due to peptidoglycan degrada-
tion.
Evaluation of different endolysins as fusion partners. The
PCNP tag was also fused to four additional endolysins from our
collection, one with a modular structure (2012-1gp229) and
three smaller ones comprising only a single catalytic domain (7,
20) (LoGT-015 to LoGT-018) (Fig. 1; see also Tables S2 and S3 in
the supplemental material). We measured the effect of the PCNP
fusion on the enzymatic activity of the different endolysins (see
Table S6) and analyzed the bactericidal effect of these new Arti-
lysins on P. aeruginosa PAO1 and Br667, Pseudomonas putida,
Burkholderia pseudomallei,E. coli, and S. Typhimurium (Fig. 4; see
also Table S7). Despite a (52% to 94%) reduction in enzymatic
activity in comparison to the corresponding wild-type endolysins,
all PCNP-fused endolysins showed improved antibacterial activ-
ity. In addition,modularity—and/or its associated high enzymatic
activity (7)—is a key factor for the success of the Artilysin ap-
proach. Besides the reductions in the cell counts of P. putida (4.89
 0.02 log) and B. pseudomallei (4.81  0.05 log), the cell count
for the multidrug-resistant P. aeruginosa Br667 strain was also
drastically reduced by 4.27 0.15 log within 30min using a single
dose (1.5M) of LoGT-001 in the presence of 0.5 mMEDTA (see
Table S7).
Optimization of the Artilysin approach. To further optimize
the potential of the PCNP tag, a set of 31 related variations of the
same fusion with both endolysins (OBPgp279 and PVP-
SE1gp146) was produced (LoGT-019 to LoGT-049) (Fig. 1; see
also Tables S2 and S3 in the supplemental material). These varia-
tions encompass various linker lengths between the polycationic
tag and the endolysin and the N- or C-terminal fusions of the tag
to the endolysin, aswell as combinatorial double-tag fusions of the
PCNP with additional hydrophobic or amphipathic moieties (see
Table S1). With the latter variations, we aimed to respond to dif-
ferences in LPS structure between P. aeruginosa and E. coli or
S. Typhimurium with a corresponding shift from ionic interac-
tions to hydrophobic packing as the major LPS stabilization force
(21). The effect on protein yield and enzymatic activity (see Ta-
ble S8) and on their antibacterial effect against P. aeruginosa,
E. coli, S.Typhimurium, andAcinetobacter baumannii, both in the
absence and presence of 0.5 mM EDTA (see Table S9), was ana-
Briers et al.
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lyzed. An increasing length of the linker between the N-terminal
PCNP tag and the endolysin results in a slightly higher antibacte-
rial effect against P. aeruginosa for Artilysins derived from
OBPgp279, with up to a 3.41 0.18 log reduction for LoGT-023
in the absence of EDTA (Fig. 5A). N-terminal fusions generally
show higher antibacterial activity than C-terminal fusions (see
Table S9). No surviving P. aeruginosa cells could be detected after
coincubation with the best Artilysins (LoGT-020, LoGT-021,
LoGT-022, and LoGT-023) in the presence of 0.5 mM EDTA,
which also almost completely eradicatedA. baumannii (up to 5.33
 0.20 log). In the case of E. coli, four of eight double-tagged
Artilysins (LoGT-037, LoGT-038, LoGT-041, and LoGT-042),
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FIG 1 Visual representation of engineered Artilysins. Seven different endolysins (OBPgp279 [YP_004958186.1], PVP-SE1gp146 [YP_004893953.1],
phiKZgp144 [NP_803710.1], 2012-1gp229 [YP_001956952.1], CR8gp3.5 [unpublished], P2gp09 [NP_046765.1], and PsP3gp10 [NP_958065.1) were selected
for modification with different peptides. (A) Single N-terminal fusion constructs, (B) double N-terminal fusion constructs, (C) N-terminal extended-linker
constructs, (D) C-terminal extended-linker constructs. Abbreviations: PCNP polycationic peptide, HPP hydrophobic pentapeptide, Pa1 Parasin1, Ly1
 lycotoxin1, L linker unit consisting of GAGA sequence.
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combining the PCNP tag with a hydrophobic peptide (HPP;
MW1) or amphipathic peptide (MW2), showed an improved bac-
tericidal effect in comparison to the single-tagged Artilysin LoGT-
001, with reductions of up to 2.22 0.09 log (Fig. 5B). In the case
of S. Typhimurium, no improvement could be obtained using the
double-tag approach. Altogether, LoGT-023, comprising a 16-
amino-acid linker between the N-terminal PCNP tag and
OBPgp279, represents the best optimization of LoGT-001, with
strong antibacterial activity against P. aeruginosa (5.50 log) and
A. baumannii (5.18  0.17 log) and moderate activity against
E. coli (2.41  0.08 log) and S. Typhimurium (1.52  0.07 log)
(Fig. 5C).
Artilysins are effective on infected human keratinocytes.
Barrier-disrupted skin, such as in burn wounds, is easily infected
by different Gram-negative bacteria, most importantly by the op-
portunistic pathogens P. aeruginosa and A. baumannii (22). Such
topical infections in humans and animals are therefore of primary
interest for Artilysin applications. LoGT-008 showsMICs of 4 and
8 g/ml against P. aeruginosa and A. baumannii, respectively. In
molar concentrations, these values equate to 0.15 and 0.30 M,
which are in the same range as the value for ciprofloxacin
(0.5 M), a common therapeutically used first-line antibiotic for
many Gram-negative infections. To evaluate LoGT-008 against
P. aeruginosa in skin infections, we developed a new human neo-
natal foreskin keratinocyte model (23). This model relies on a
confluent keratinocyte monolayer, infected with P. aeruginosa
PA14 (105 or 107 CFU/ml). At 1 h after infection, 2 M PVP-
SE1gp146 or LoGT-008 was added. Keratinocyte viability and
bacterial reductions were quantified at 4 h after infection. Both
PVP-SE1gp146 and LoGT-008 could fully protect (100%) the
monolayer from the otherwise cytotoxic effects upon a PA14 in-
fection with 105 CFU/ml (Fig. 6A). This protection is associated
with a drastic decrease in bacterial load. A larger bacterial inocu-
lum of 107 CFU/ml was found to cause 97%mortality within 4 h.
Under these extreme circumstances, a single dose of LoGT-008
could still rescue 27% of the keratinocytes (significantly more
than the 14% rescued by the native endolysin; P  0.05). Corre-
spondingly, the bacterial loadwas reduced significantly (P 0.05)
in the presence of LoGT-008 (71% versus 31% for the native en-
dolysin) (Fig. 6B).
Artilysins show in vivo antibacterial efficacy. Since the PCNP
fusions provide endolysins with in vitro antibacterial activity
against pseudomonads in both suspension and keratinocyte cul-
tures, we used a C. elegans nematode gut infection model (24) to
evaluate the in vivo efficacy of a PCNP-fused Artilysin, LoGT-008,
against bacterial infection.WhenC. elegans grazed on the selected,
highly virulent P. aeruginosa PA14 strain, 90% of the nematodes
were killed within 5 days after infection (see Fig. S1 in the supple-
mental material). Nematode survival rates were compared after
treatment with the native PVP-SE1gp146 endolysin and the cor-
responding LoGT-008, using ciprofloxacin as a positive control
(Fig. 7). In the presence of 0.5 mM EDTA, PVP-SE1gp146 could
rescue 40% 7% of the infected worms after 5 days. In the same
assay, LoGT-008 showed a significant (P 0.01) protective effect
in the longer term (63% 4% survival) versus 45% 5% survival
after treatment with ciprofloxacin.
DISCUSSION
The concept of endolysins as antibacterials against Gram-positive
pathogens was postulated in 1991 by Gasson (25) and proven in
2001 by Nelson et al., reporting the prevention and elimination of
group A streptococcus colonization in the upper respiratory tract
of mice (1). Since then, a multitude of endolysins active against
diverse Gram-positive pathogens have been described, while
Gram-negative targets have been largely neglected (5). We have
previously reported the efficacy of a combination of high hydro-
static pressure (9) or outer membrane permeabilizers (10) with
endolysins against Gram-negative species.We, and other authors,
also described the existence of some endolysins that have moder-
ate intrinsic antibacterial activity against P. aeruginosa, most likely
because they can interact with and partially pass across the outer
membrane barrier (7, 8). In this study, we showed that tailoring
highly active, modular phage endolysins with a polycationic pep-
tide turns them in potent antibacterials that are active against a
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FIG 2 Antibacterial activity of the N-terminal fusion variants of OBPgp279
and PVP-SE1gp146. (A) Fourteen Artilysins with N-terminal fusions of seven
different peptides (see Table S1 in the supplemental material) to OBPgp279
and PVP-SE1gp146 are compared to the corresponding unmodified endoly-
sins for their antibacterial activity against P. aeruginosa PAO1. This compari-
son shows the PCNP to be themost effective peptide among the seven peptides
tested here. (B) Comparison of the antibacterial activities of two wild-type
endolysins (OBPgp279 and PVP-SE1gp146) and their PCNP-tagged Artilysin
counterparts (LoGT-001 and LoGT-008, respectively) with and without
0.5 mM EDTA. Activity was tested on P. aeruginosa strains PAO1 and
multidrug-resistant Br667, both in the absence (wt endolysin, white bars; Arti-
lysin, light gray bars) and presence (wt endolysin, dark gray bars; Artilysin,
black bars) of 0.5 mM EDTA. These data show that the PCNP fusion for the
antibacterial activity of the endolysin added value while not compromising its
synergy with EDTA. Averages and standard deviations of results of three rep-
licates are shown.
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broad range of important Gram-negative pathogens. Through
this engineering, endolysins acquire autonomous antibacterial ac-
tivity, and in the case of OBPgp279, which itself possesses intrinsic
activity, the antibacterial effect is further enhanced to the same
extent as for PVP-SE1gp146. Time-lapse microscopy of cells ex-
posed to LoGT-008 confirmed that cells are indeed killed through
cell lysis as a consequence of peptidoglycan degradation. There-
fore, the endolysinmoietymust have been transferred through the
outer membrane, most likely because of the competitive displace-
ment of stabilizing divalent cations of the LPS layer by the poly-
cationic nonapeptide. The reduced enzymatic activity after PCNP
fusion does not impede the strong antibacterial activity; however,
considering that the most active (modular) endolysins generally
show the best antibacterial effect, fusions that maintain the high
enzymatic activity of such endolysins may represent a further op-
timization of novel Artilysins.
Extension of the flexible linkers between the penetrating pep-
tide and the endolysins generally improves the antibacterial activ-
ity at up to 3.41 0.18 against P. aeruginosa PAO1 in the case of
LoGT-023 in the absence of EDTA. N-terminal fusions perform
better than C-terminal fusions of OBPgp279 and PVP-SE1gp146;
however, it appears that both the optimal fusion side and linker
length are best tested empirically. In specific cases, a combinato-
rial double-tag approach gives some significant improvements as
well, as shown for different Artilysins against E. coli. Importantly,
in all cases, the strong synergy with EDTA is maintained, giving
0:00 0:20
7:40 8:00
1:40 2:00
20:40 21:00
0:00 0:20
3:40 5:40
1:40 3:20
42:20 42:40
A
B
FIG 3 Time-lapse series of the action of LoGT-008 on P. aeruginosa PAO1. Cells were mixed with LoGT-008 in the presence of 0.5 mM EDTA and were
subsequently recorded using time-lapse microscopy. Time points are indicated (min:s). Scale bar, 2 m.
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rise to combinations that reduce cell counts more than 5.50 log
(the detection limit) in vitro.
The variation in LPS structure appears to be a key determinant
for the sensitivity to Artilysins. We specifically focused on the
applicability to P. aeruginosa, an important emerging multidrug-
resistant pathogen. P. aeruginosa LPS has a high phosphate con-
tent and consequently a higher concentration of divalent cations
stabilizing its structure (12). These cations are simultaneously the
strength and Achilles’ heel of the P. aeruginosa LPS layer. EDTA
and polycationic peptides act on this same site but through two
different mechanisms, chelation and competitive displacement,
respectively (26). The lower phosphorylation degree in E. coli and
S. Typhimurium LPS is compensated by increased hydrophobic
packing of the lipid Amoiety through a higher degree of acylation
with longer acyl chains (12). This variationmay explain the higher
sensitivity of P. aeruginosa strains compared to that of E. coli and
S. Typhimurium and the increased activity against E. coli of some
double tags that combine polycationicity and hydrophobicity/
amphipathicity.
Given the proteinaceous nature of Artilysins, theymay be con-
sidered biodegradable compounds that are less likely to accumu-
late or induce resistant bacteria in the environment. In contrast,
many antibiotics persist in the environment, leading to an in-
creased risk of selecting resistant bacteria, especially when envi-
ronmental bacteria are exposed to subtherapeutic antimicrobial
concentrations (27). This detrimental side effect of many nonbio-
degradable antimicrobials may be nonexistent for Artilysins.
Recently, Lukacik and coworkers (11) described an alternative
approach to ensure transport of an endolysin across the outer
membrane by constructing a hybrid of T4 lysozyme and the FyuA
binding domain of pesticin. Reduction of the cell count of about 1
log in 24 h depends on the presence of the TonB-dependent outer
membrane transporter FyuA. Besides restriction to Yersinia spe-
cies and uropathogenic E. coli strains that express FyuA, this FyuA
dependence may also quickly result in resistance development by
shutting down fyuA expression or the accumulation of point mu-
tations in the fyuA genes. Eukaryotic lysozymes have also been
subjected to recombinant fusionwith diverse peptides or chemical
modifications to render them active against Gram-negative bac-
teria. Various modifications of the cationic hen egg white ly-
sozyme (HEWL) or human lysozyme have been constructed to
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FIG 4 Antibacterial activity of PCNP-Artilysins based on different endoly-
sins. The effect on antibacterial activity of anN-terminal PCNP fusion to three
modular (OBPgp279, PVP-SE1gp146, and 2012-1gp229) and three globular
(PsP3gp10, P2gp09, and CR8gp3.5) endolysins is shown for P. aeruginosa
PAO1. Averages and standard deviations of results of three replicates are
shown. wt, wild type.
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FIG 5 Optimization of PCNP-based Artilysins. (A) The effect of an increas-
ing length of the flexible linker between PCNP and OBPgp279 on the antibac-
terial activity against P. aeruginosa PAO1 is shown. L0, L1, L2, L3, and L4
correspond to intervening amino acid sequences of AGAS, AGAGAS,
AGAGAGAGAS, AGAGAGAGAGAGAS, and AGAGAGAGAGAGAGAGAS.
(B) The antibacterial activity of Artilysins comprising a tandem of the PCNP
peptide and a second peptide as N-terminal fusions to OBPgp279 is compared
to that of PCNP-OBPgp279 (LoGT-001) in the absence (light gray) and pres-
ence (dark gray) of 0.5 mM EDTA. (C) LoGT-023, comprising a 16-amino-
acid flexible linker between the N-terminal PCNP tag and OBPgp279, gener-
ally appeared the most effective Artilysin. The antibacterial activity against
P. aeruginosa, A. baumannii, E. coli, and S. Typhimurium in the presence of
0.5 mM EDTA is shown. Averages and standard deviations of results of three
replicates are given.
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increase their hydrophobicity, generating amphitropic proteins
with both hydrophilic and lipophilic properties (for a review, see
reference 28). These modifications expand the activity range of
HEWL to Gram-negative E. coli. The highest antibacterial activity
was obtained by the covalent attachment of one stearoyl or two
palmitoyl acids or by a C-terminal fusion to a hydrophobic pen-
tapeptide (Phe-Phe-Val-Ala-Pro, which has approximately the
same length as one palmitoyl acid); however, the maximal bacte-
rial reduction by theseHEWLmodifications remained below 1 log
(29–31).
Multidrug-resistant Gram-negative pathogens are particularly
troublesome, because they have intrinsic or acquired resistance to
nearly all drugs that can be currently considered for treatment.
This worrisome situation also exists, but not to the same extent,
for some Gram-positive infections (e.g., Staphylococcus and En-
terococcus). The most prevalent Gram-negative pathogens are En-
terobacteriaceae, P. aeruginosa, and Acinetobacter, all subjects of
this study, and infections are mostly health care associated (32).
This report shows that Artilysins can drastically expand the spec-
trum of endolysins as a novel class of promising anti-infectives
(33), making Gram-negative species susceptible to these new
enzyme-based antibacterials. The activity of Artilysins in two dif-
ferent settings (C. elegans bacterial infection model and keratino-
cytes) shows that Artilysins may have a potentially broad field of
applications ranging from topical, mucosal, and gastrointestinal
medical use to disinfection, veterinary, food, feed, and agricultural
applications.
MATERIALS AND METHODS
Bacterial strains. Pseudomonas aeruginosa PAO1 (ATCC 15692), origi-
nally a wound isolate, is now a widely used laboratory strain (34). The
clinical P. aeruginosa strains Br667, a multiresistant (10 of 11 antibiotics)
burnwound isolate collected in the intensive care unit in theQueenAstrid
Military Hospital in Brussels, Belgium, PA14, a highly virulent wound
isolate from Boston, MA, and other clinical P. aeruginosa strains were all
provided by J.-P. Pirnay (19, 35). Pseudomonas putida G1 was isolated
fromRussian soil in the neighborhood ofMoscow (V. Krylov, Laboratory
of Bacteriophage Genetics). Acinetobacter baumannii 25 is an uncharac-
terized clinical isolate from the Queen Astrid Military hospital, donated
by Maya Merabishvilli (Lab MCT, Brussels, Belgium), and the Burkhold-
eria pseudomallei strain used is a clinical strain from the University Hos-
pital of Gasthuisberg (Leuven, Belgium) isolated by J. Verhaegen (Labo-
ratory of Clinical Microbiology and Mycology, UZ Leuven).
S. Typhimurium LT2 was provided by the Centre of Food and Microbial
Technology (KU Leuven, Belgium). Several different Escherichia coli
strains were used in this study: E. coli XL1-Blue MRF= (Agilent Technol-
ogies, Santa Clara, CA) for antibacterial activity testing, E. coli TOP10
(Life Technologies, Carlsbad, CA) for DNA cloning and cell stock storage,
and E. coli BL21(DE3) pLysS, BL21-CodonPlus-(DE3)-RIL, and BL21-
CodonPlus-(DE3)-RP (Agilent Technologies) as host strains for protein
expression. For proper selection, ampicillin (Roche Diagnostics, Mann-
heim, Germany) (100 g/ml) or chloramphenicol (Calbiochem, Darm-
FIG 6 Antibacterial effect of PVP-SE1gp146 and PCNP-PVP-SE1gp146
(LoGT-008) in a P. aeruginosa PA14-infected human keratinocyte monolayer.
A mixture of 2 Mof PVP-SE1gp146/LoGT-008 and 0.005 mM of EDTA was
applied to a 5-day-old confluent keratinocyte monolayer that was infected
with 105 CFU/ml (A) or 107 CFU/ml (B) P. aeruginosa PA14 1 h before treat-
ment. Numbers of surviving bacteria (squares) and surviving keratinocytes
(bars) were quantified after 4 h of infection. Proportions of surviving bacteria
are shown relative to the infected, untreated control results. Significantly dif-
ferent conditions (P 0.05) are indicated with bold (keratinocyte survival) or
italic (bacterial survival) letters.
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FIG 7 Survival rates of P. aeruginosa PA14-infected C. elegans SS104 nema-
todes treated with PVP-SE1gp146 or PCNP-PVP-SE1gp146 (LoGT-008) in
combination with EDTA. PVP-SE1gp146 (5 MIC; o) or LoGT-008 (5
MIC; Œ) was added to infected nematodes in the presence of 0.5 mM EDTA.
Ciprofloxacin (e; 5 MIC) was used as a positive control for antibacterial
activity. Other controls included were untreated PA14-infected nematodes
(Œ), untreated nematodes grown on E. coli OP 50 (), and EDTA-treated
infected nematodes (). A total of 30 infected worms were used for each
condition. Nematode viability, in percentages relative to initial values at day 0,
was assessed at different time points after compound addition (day 0). Aver-
ages and standard deviations of results of three independent experiments are
shown. Significantly different conditions (P 0.05) are marked.
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stadt, Germany) (50 g/ml) was used. All strains were grown at 37°C,
except for P. putida G1 (30°C), in lysogeny broth (LB).
Plasmid construction. Overviews of all LPS-destabilizing peptides
and produced Artilysins are given in Tables S1 to S3 in the supplemental
material and Fig. 1, respectively. Open reading frames (ORFs) encoding
the different endolysins were amplified (Pfu polymerase; Thermo Fisher
Scientific, Waltham, MA) with purified genomic DNA isolated from the
respective phages as template DNA. Cloning into the pEXP5CT/TOPO
expression vector was performed according to the manufacturer’s guide-
lines (Life Technologies). The polycationic nonapeptide (PCNP) and the
hydrophobic pentapeptide (HPP) were fused to endolysins by a standard
PCR on purified genomic DNA of the respective phages using forward
(N-terminal fusion) or reverse (C-terminal fusion) primers that harbor
the peptide-encoding sequence. For N-terminal fusion of the 4, MW1,
MW2, Lycotoxin1, and Parasin1 peptides, an adapted version of the
ligation-independent cloning (LIC) technique (36) was used. Briefly,
peptide-encoding cassettes, created by hybridization of specific primer
pairs (20 M each), were treated with a mixture of dCTP (Promega,
Agora, WI) and T4 DNA polymerase (Thermo Fisher Scientific) to intro-
duce LIC-compatible 5= sticky ends. In parallel, the endolysin-encoding
expression vectors weremade LIC compatible by introduction of a unique
Ecl136II restriction endonuclease site upstream of the endolysin-
encoding ORF using a standard PCR (see intermediate constructs in Ta-
ble S3 in the supplemental material). The procedure was followed by
linearization with Ecl136II endonuclease (New England Biolabs, Ipswich,
MA) and creation of complementary sticky ends by treatment with dGTP
(Promega) and T4 DNA polymerase. A short incubation step of the hy-
bridized peptide-encoding cassettes with the LIC-compatible vectors
completed the cloning process. Two different types of double-tag fusions
were constructed in this study: type 1, with the PCNP located
N-terminally to the second peptide and the endolysin (type 1 conforma-
tion: PCNP—second peptide—endolysin), and type 2, with the PCNP
between the second peptide and the endolysin (type 2 conformation: sec-
ond peptide-PCNP-endolysin). For the type 1 configuration, a standard
PCR with a PCNP peptide-encoding 5= primer (Pfu polymerase) was ap-
plied on purified pEXP5-CT/4-endolysin and pEXP5-CT/HPP-
endolysin plasmid DNA, respectively. To obtain type 2 double-tag fu-
sions, the same adapted version of the LIC method was used as described
for the single-peptide fusion, except that the pEXP5CT/PCNP-endolysin
vector was used as the template. All type 1 and type 2 fusion constructs
were introduced in the pEXP5CT-TOPO expression vector. To construct
plasmids with extended linkers between the PCNP-encoding sequence
and the endolysin-encoding ORF, a standard PCR was first used to intro-
duce NheI and NgoMIV restriction sites for directional cloning. Upon
double digestion of the obtained pEXP5CT/PCNP-NheI-NgoMIV-
endolysin (for N-terminal end) and pEXP5CT/endolysin-NgoMIV-
NheI-PCNP (for C-terminal end) constructs (NgoMIV, New England
Biolabs; NheI, Thermo Fisher Scientific), cassettes of various lengths with
5= complementary sticky ends (encoding the following amino acid se-
quences: larval stage 1 [L1] GAGA, L2 GAGAGAGA, L3 GAGAG
AGAGAGA, L4GAGAGAGAGAGAGAGA), obtained through hybrid-
ization of specific primer pairs (20M each), were inserted in the vectors
(T4 ligase; Thermo Fisher Scientific).
Recombinant expression and purification. Recombinant expression
of the different constructs was performed in an E. coli-based expression sys-
temupon inductionof exponentially growing cells (optical density at 600nm
[OD600] 0.6) with 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG;
Thermo Fisher Scientific), unless otherwise stated. Expression conditions
(temperature, time, and expression strain) differed depending on the pro-
tein to optimize the soluble-expression levels for each construct (see Ta-
ble S3 in the supplemental material). Expression was stopped by centrif-
ugation (3,900  g, 30 min, 4°C), and the obtained cell pellet was
resuspended in a 1/25 vol of lysis buffer (20mMNaH2PO4 [Merck,Darm-
stadt, Germany]/NaOH, 0.5 M NaCl, pH 7.4). This cell lysate was then
subjected to three freeze-thaw cycles (80°C/22°C) prior to sonication
(Vibra-Cell Sonics, Newtown, CT) (8 cycles of a 30-s pulse and 30-s rest;
amplitude of 40%). The protein lysate was then filtered through 0.45- and
0.22-m-pore-size Durapore membrane filters (Millipore, Billerica,
MA). Purification of theHis6-tagged fusion proteins was performed on an
Aktä fast protein liquid chromatography (FPLC) system (GE Healthcare,
Buckinghamshire, United Kingdom) controlled by UNICORN 5.1 soft-
ware with Ni2-nitrilotriacetic acid (NTA) columns (HisTrap HP; GE
Healthcare) (1 ml). The wash buffer used in the purification process con-
tains a low protein-dependent imidazole concentration (50 to 80mM) for
higher purification stringency (see Table S3). After dialysis to an appro-
priate buffer, the protein concentration was determined spectrophoto-
metrically in silica cuvettes at a wavelength of 280 nm (Ultraspec III spec-
trophotometer; GE Healthcare).
Muralytic assay. Outer-membrane-permeabilized cells were used as
the substrate (37). Briefly, P. aeruginosa PAO1 cells growing in the mid-
exponential phase (OD600  0.6) were spun down (3,900  g, 30 min,
4°C) and subsequently incubatedwith gentle shaking for exactly 45min in
chloroform-saturated 0.05 M Tris-HCl (pH 7.7). Cells were then washed
in aKH2PO4/K2HPO4 buffer (ionic strength 80mM, pH7.2) to remove
residual chloroform and concentrated to an OD600 of 1.5. Upon addition
of 30 l of muralytic enzymes (at from 10 to 2,000 nM) to 270 l of
outer-membrane-permeabilized cells, the optical density was measured
spectrophotometrically over time at 655 nm using a Microplate Reader
680 system (Bio-Rad). A standardized calculation method to quantify the
muralytic activities of lytic enzymes using this assay was described before
(38).
Antibacterial assays. Gram-negative cells growing in the mid-
exponential phase (OD600 0.6) were diluted 100-fold in 5 mMHEPES/
NaOH (pH 7.4) to a final density of 106 CFU/ml. Each cell culture
(100 l) was incubated for 30 min at room temperature with 50 l endo-
lysin/Artilysin dialyzed against phosphate-buffered saline (PBS) (pH 7.4)
and 50l 5mMHEPES/NaOH (pH 7.4) buffer or 50l 2mMEDTA-Na2
(abbreviated as EDTA; final concentration of 0.5 mM) dissolved in the
same buffer. After 30 min of incubation, appropriate dilutions of cell
suspensions were plated on LB agar in triplicate. Colonies were counted
after overnight incubation at 37°C. The antibacterial activity was quanti-
fied as the relative inactivation level in log units [log10(N0/Ni), withN0
initial number of untreated cells and Ni  number of residual cells
counted after treatment). The MIC of LoGT-008/ciprofloxacin against
P. aeruginosa PAO1 and A. baumannii 25 in the presence of EDTA in
96-well plates was determined using the broth microdilution method.
Cells were diluted according to the McFarland standard in low-salt LB
(10 g/liter tryptone, 5 g/liter yeast extract). A dilution series of LoGT-008/
ciprofloxacin was added, and the plate was incubated for 18 h at 37°C. All
measurements were performed in comparison to a negative control (me-
dium without bacteria) or a positive control (medium without LoGT-
008). The MIC was defined as the minimum concentration that com-
pletely inhibited bacterial growth.
Time-lapse microscopy. A temperature-controlled (Okolab Otta-
viano, Italy) Ti-Eclipse inverted microscope (Nikon, Champigny-sur-
Marne, France) equipped with a TI-CT-E motorized condenser and a
CoolSnap HQ2 FireWire charge-coupled-device (CCD) camera was used
as described previously (39). P. aeruginosa PAO1 cells were grown to
mid-exponential phase (OD600  0.6), washed three times with PBS
(pH 7.4), and finally concentrated five times by resuspension in PBS–
0.5 mM EDTA-Na2. LoGT-008 was added to reach a final concentration
of 0.5 mg/ml. For imaging, samples were placed on a PBS–0.5 mM
EDTA–Na2–agar pad and a cover glass, essentially as described previously
(39), and incubated at 37°C. The time between addition of LoGT-008 to
the cells and recording was kept as short as possible (~60 s). Images were
acquired using NIS-Elements (Nikon), and the resulting pictures were
further handled with ImageJ open source software (downloaded from
http://rsbweb.nih.gov/ij/) and CorelDRAW X5.
Human keratinocyte assays. Keratinocytes were seeded in coated
(1 g/ml collagen type I for a minimum of 2 h at 37°C) 25-cm2 vented
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culture flasks at 5,000 cells/cm2 and cultured until more than 90% con-
fluence was reached (supplemented EpiLife medium; 6 days, 37°C, 5%
CO2, and 95% relative humidity). Confluent grown keratinocytes were
infected with clinical P. aeruginosa PA14 strains at an infectivity dose of
105 or 107CFU/ml. At 1 h after infection, both the unmodified andPCNP-
modified endolysins (2Mfinal concentration)were added together with
EDTA (5 M final concentration) to the keratinocyte cultures. Unin-
fected keratinocytes and infected but untreated keratinocytes were in-
cluded as negative controls. After an additional 3 h of incubation, the
infection process was stopped by trypsinization of the residual keratino-
cytes (TrypLE Select recombinant trypsin [Life Technologies]) for 5 min
at 37°C and washing in supplemented EpiLife medium. The cell suspen-
sions were collected and centrifuged at 170 g for 10 min. After centrif-
ugation, the cells were resuspended in supplemented EpiLife medium.
Keratinocyte viability was microscopically evaluated (Bürker chamber)
using trypan blue live/dead staining. Living keratinocytes appeared as
colorless cells under the microscope, whereas dead ones became blue due
to their disintegrated cell membrane. For evaluation of the antibacterial
activity of the P. aeruginosa strains, 10-fold dilutions of the keratinocyte
culture were plated on LB agar and the residual bacterial CFUswere quan-
tified for each condition after 18 h of incubation at 37°C. The antibacterial
activity is expressed in percent reduction relative to the untreated negative
control. Multiple pairwise t test comparisons were performed (P 0.05)
to classify the different conditions in significantly different groups for
keratinocyte (bold labels) and bacterial (italic labels) viability.
C. elegans infection assay. Caenorhabditis elegans SS104, genotype
glp-4(bn2), wasmaintained at 16°Connematode growthmedium (NGM)
agar covered with a lawn of E. coliOP 50 as a feed source (40). Nematode
experiments were performed with synchronized L4-stage nematodes ac-
quired by adult bleaching and hatching of the eggs at 16°C for 4 days. For
infection of C. elegans SS104, 50 synchronized L4-stage nematodes were
seeded on bacterial lawns of P. aeruginosa PA14. Lawns were prepared by
spreading 100l of culture at the stationary phase of growth on top of the
NGM agar and incubation at 37°C for 18 h before seeding. The infection
took place for 24 h at 26°C. Nematode survival after infection was evalu-
ated by the liquid assay as described before (41, 42). Briefly, infected
nematodes were washed three times with M9 buffer to remove attached
bacteria and transferred to 96-well plates (~10 nematodes per well).Wells
contained 100 l of an NGM/M9 buffer (1:4) mixture, 50 l (PCNP)
endolysin dialyzed against PBS (pH 7.4), and 50 l EDTA (0.5 mM final
concentration)–PBS (pH7.4). In addition, PBSbuffer (pH7.4) andEDTA
were added as negative controls and ciprofloxacin (Sigma-Aldrich) (5
MIC) as a positive control. Each condition was tested at a 10-fold level.
Survival of C. elegans SS104 was determined by monitoring the presence
or absence of touch-provoked movement for each nematode during 5
subsequent days. Dead nematodes appear as long, immobile rods; living
ones move in a sinusoidal shape (41, 42). Multiple pairwise t test compar-
isons were performed (P  0.05) to classify the tested conditions in sig-
nificantly different groups for C. elegans survival after 5 days.
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